Translational Research Methods for the Metabolic Continuum : A Focus on Early Phase Clinical Drug Development (3. Aufl.)

個数:
  • 予約

Translational Research Methods for the Metabolic Continuum : A Focus on Early Phase Clinical Drug Development (3. Aufl.)

  • 現在予約受付中です。出版後の入荷・発送となります。
    (重要:表示されている発売日は予定となり、発売が延期、中止、生産限定品で商品確保ができないなどの理由により、ご注文をお取消しさせていただく場合がございます。予めご了承ください。)

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版
  • 商品コード 9783032304995

Full Description

In this 3rd edition, we position metabolic fatty liver disease (MAFLD) more prominently both as a component and driver of a metabolic continuum of non-communicable disorders. These include obesity, diabetes, cardiovascular, and renal disease.  All share common risk factors and are interconnected via complex - and often bidirectional - pathological processes.

The pivotal position of MAFLD reflects increasing awareness in recent years of (a) intersections between metabolic liver disease and the broader spectrum of cardiometabolic disorders and (b) the unmet need for effective new pharmacotherapies.  

Evidence from clinical trials of medications originally developed to treat obesity and diabetes points to the need for practical non-invasive methods for quantifying therapeutic effects on hepatic steatosis.  An intense drug development effort continues aimed at the clinically important subtype of non-alcoholic steatohepatitis (NASH) which carriesan increased risk of fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, MAFLD/NASH is recognized as a multisystem disease with myriad extrahepatic manifestations.

The 3rd edition will update all chapters with particular emphasis on expanding the chapters on hepato-cardio-renal and functional imaging; the chapter on isotopic tracer methodology will also be strengthened.  Relevant new chapters in a new section will address the future prospects for biomarkers to include proteomics, metabolomics, and genomics.  The potential of computational modeling in translational research will be covered alongside the value of real-world data in drug development and strategies for personalized precision management of diseases in the metabolic continuum.

The book will continue our objective - established in the earlier editions - to remain at the forefront of clinical science that facilitates paradigm changes and provides leadership in translational research for cardiometabolic disorders. 

最近チェックした商品